Atorvastatine/clopidogrel/furosemide + NZCS MFB 7798

NZCS: natriumzirkoniumcyclosilicaat

Onderbouwend	Stof	Effect	Code
Någård M. Clinical Kidney Journal, sfaa222, https://doi.org/10.1093/ckj/sfaa222 *atorvastatine 10 mg, clopidogrel 75 mg, furosemide 20 mg NB dabigatran zit apart.	NZCS + atorvastatine, clopidogrel, furosemide	studie naar effect NZCS op 3 zwakke zuren. Regime: middel* alleen of tegelijk met NZCS 10 g 1dd; open-label, one sequence crossover studie met 24 gezonde vrijwilligers. No interaction was concluded if the 90% confidence interval for the GMR (SZC co-administration vs alone) of the PK parameters was within 80–125%. -atorvastatine: ↑Cmax atorvastatine 1.69x en o-OH atorvastatine 1.37x, geen invloed op AUC; geen effect op Cmax of AUC p-OH metaboliet; SZC is unlikely to affect low-density lipoprotein cholesterol (LDL-C) reductions by atorvastatin. -clopidogrel: toename AUC0–t 1.2x en AUCinf 1.7x; afname clopidogrelzuur metaboliet met 12% resp. 8%; afname Cmax clopidogrel zuur metaboliet met 32%; these changes are not expected to affect clopidogrel efficacy; the AUC of clopidogrel acid (predominant inactive metabolite) is >1000-fold greater than that of the parent drug and is therefore the most clinically relevant PK parameter for determining clopidogrel absorption. -furosemide: toename Cmax 1.66x, minimaal effect op AUC; afname Ttmax 1.8→1h en t1/2 6.1→4.7h. Auteurs: changes in PK profiles were observed for atorvastatin, clopidogrel and furosemide; however, the effect on Cmax was >50% for only atorvastatin and furosemide, and none of the parameters exceeded the no-interaction 90% CI range by >2-fold. Therefore these changes were not considered clinically meaningful and SZC coadministration is not expected to affect the clinical activity of these pH-sensitive drugs.	3A
SPC + EPAR Lokelma	NZCS + atorvastatine, clopidogrel, furosemide	geen klinisch relevante interacties bij gelijktijdig clopidogrel, atorvastatine, furosemide; klinisch onderzoek bij 192 gezonde proefpersonen. Geen dosisaanpassing of scheiding doseringstijd vereist.	2A

Overig	Stof	Effect
--		

Opmerkingen
Stockley: -

PubMed: niets op Sodium zirconium cyclosilicate and DI

Risicofactoren	
Mitigerende factoren	

	Interactie	Actie	Datum
Beslissing WG IA	Ja	Nee	21 oktober 2021